Last reviewed · How we verify
CTA control
At a glance
| Generic name | CTA control |
|---|---|
| Sponsor | ImevaX |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease (NA)
- Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients. (NA)
- Application of VascuLens 2.0, A Mixed Reality System for Surgical Guidance During DIEP Flap Harvest (PHASE1)
- Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events (PHASE3)
- Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE (PHASE4)
- REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial (PHASE3)
- A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China (NA)
- Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CTA control CI brief — competitive landscape report
- CTA control updates RSS · CI watch RSS
- ImevaX portfolio CI